Circulation, Vol 78, 227-232, Copyright © 1988 by American Heart Association
CA Muller, LH Opie, CW Hamm, M Peisach, CA Pineda and FT Thandroyen
Antiarrhythmic and hemodynamic effects of the calcium channel antagonist
verapamil were compared with those of tiapamil, a congener, in open-chest
pigs with anterior descending coronary artery ligation. Tiapamil (6 mg/kg
i.v.) decreased the incidence of ventricular fibrillation to 4 of 10 versus
22 of 25 in controls (p less than 0.05) and maintained left ventricular
dP/dtmax after ligation (predrug value: 2,312 +/- 112 mm Hg/sec; 20 minutes
after ligation: 2,139 +/- 229 mm Hg/sec). Tiapamil increased blood flow in
the peripheral ischemic zone (24 +/- 3.2% vs. 16.9 +/- 1.6% of preligation
value in controls, p less than 0.05) as well as in the peri-ischemic and
nonischemic zones (153.9 +/- 12.7% and 186.3 +/- 17.1%, respectively; both
p less than 0.0001 vs. 97.9 +/- 5% and 91.3 +/- 4.7% in controls).
Verapamil (0.6 mg/kg i.v.) decreased the incidence of ventricular
fibrillation to 0 of 7 versus 22 of 25 in controls (p less than 0.005);
left ventricular dP/dtmax decreased from 2,062 +/- 144 to 1,060 +/- 168 mm
Hg/sec (p less than 0.0001). Verapamil did not change blood flow in the
peripheral, peri-ischemic, or nonischemic zones. Thus, tiapamil, and not
verapamil, decreased ischemic ventricular fibrillation while maintaining
left ventricular mechanical function. Verapamil congeners warrant further
evaluation as antiarrhythmic agents in acute myocardial ischemia.
ARTICLES
Verapamil and tiapamil in prevention of ventricular fibrillation in pigs with coronary ligation. Comparative effects on left ventricular function
Ischaemic Heart Disease Research Unit, Medical Research Council, Cape Town, South Africa.
This article has been cited by other articles:
![]() |
O. Aydin, R. Becker, P. Kraft, F. Voss, M. Koch, K. Kelemen, H. A. Katus, and A. Bauer Effects of protein kinase C activation on cardiac repolarization and arrhythmogenesis in Langendorff-perfused rabbit hearts Europace, November 1, 2007; 9(11): 1094 - 1098. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Muller, L. H. Opie, J. McCarthy, D. Hofmann, C. A. Pineda, and M. Peisach Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise J. Am. Coll. Cardiol., July 1, 1998; 32(1): 268 - 274. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1988 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |